Provectus Biopharmaceuticals, Inc. (OTC:PVCT) Q4 2024 Results Conference Call November 14, 2024 2:00 PM ET
Company Participants
Alyssa Barry – Co-Founder & Principal of Investor Relations, Alliance Advisors IR
Ed Pershing – Chairman
Dominic Rodrigues – Board Vice Chairman
Alyssa Barry
Good afternoon, good morning, good evening, depending on where you are. Welcome to Provectus Biopharmaceuticals Fourth Quarter Investor Update. My name is Alyssa Barry, Co-Founder and Principal of Investor Relations firm Alliance Advisors IR.
I am hosting today’s call. Ed Pershing, Chairman of Provectus’ Board of Directors and Chief Executive Officer; and Dominic Rodriguez, Board Vice Chairman and President, will provide the company updates and their remarks today.
Following the presentation, we will conduct a question-and-answer session. This presentation is being recorded, and a replay will be available on Provectus’ website. Management has cameras turned-off at the moment, but we will be turning them on for the Q&A portion of today’s call.
Today’s discussion includes forward-looking statements. As always, we want to caution you that such statements are based on management’s assumptions and beliefs. This forward-looking statements are subject to uncertainties and other factors that could cause actual results to differ materially from such statements. Please see Provectus’ public filings for a discussion of these risk factors.
I will now turn the call over to Ed for his opening remarks.
Ed Pershing
Thank you, Alyssa.
First, I want to express my appreciation to each of you in attendance for this update, as we appreciate your interest in Provectus and our future success. We believe Provectus’ value will be determined by the unique capabilities of Rose Bengal Sodium, RBS molecule, the company’s proprietary synthesis process for manufacturing pharmaceutical grade RBS, and the numerous potential global market opportunities to address different unmet medical needs in an affordable and accessible manner for patients.
